TY - JOUR
T1 - A new model to study spinal muscular atrophy
T2 - Neurite degeneration and cell death is counteracted by BCL-XL Overexpression in motoneurons
AU - Garcera, Ana
AU - Tasheva, Stefka
AU - Gou-Fabregas, Myriam
AU - Caraballo-Miralles, Víctor
AU - Lladó, Jerònia
AU - Comella, Joan X.
AU - Soler, Rosa M.
N1 - Funding Information:
This work was supported by grants from GENAME (Defining targets for Therapeutics in SMA) to RMS and JLl; from Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [ PI080267 ], Generalitat de Catalunya [ SGR740 ], and Consolider-Ingenio 2010 [ CSD2007-00020 ] to RMS. AG holds a postdoctoral contract from Genoma España; MGF holds a fellowship from Universitat de Lleida; and SM holds a fellowship from Comissionat de Universitats i Recerca, Departament d'Innovació, Universitats i Empresa de la Generalitat de Catalunya i Fons Social Europeu. We thank Elaine Lilly, Ph.D. (Writer's First Aid), for English language revision of the manuscript and Montserrat Rue, Ph.D., for her advice on statistical analysis.
PY - 2011/6
Y1 - 2011/6
N2 - Spinal muscular atrophy (SMA) is a motoneuron disorder characterized by deletions or specific mutations in the Survival Motor Neuron gene (SMN). SMN is ubiquitously expressed and has a general role in the assembly of small nuclear ribonucleoprotein (snRNP) and pre-mRNA splicing requirements. However, in motoneuron axons SMN deficiency results in inappropriate levels of certain transcripts in the distal axon, suggesting that the specific susceptibility of motoneurons to SMN deficiency is related to a specialized function in these cells. Although mouse models of SMA have been generated and are useful for in vivo and in vitro studies, the limited number of isolated MNs that could be obtained from them makes it difficult to perform biochemical, genetic and pharmacological approaches. We describe here an in vitro model of isolated embryonic mouse motoneurons in which the cellular levels of endogenous SMN are reduced. These cells show neurite degeneration and cell death after several days of SMN knockdown. We found that the over-expression of the anti-apoptotic protein Bcl-xL into motoneurons rescues these cells from the phenotypic changes observed. This result demonstrates that Bcl-xL signaling could be a possible pharmacological target of SMA therapeutics.
AB - Spinal muscular atrophy (SMA) is a motoneuron disorder characterized by deletions or specific mutations in the Survival Motor Neuron gene (SMN). SMN is ubiquitously expressed and has a general role in the assembly of small nuclear ribonucleoprotein (snRNP) and pre-mRNA splicing requirements. However, in motoneuron axons SMN deficiency results in inappropriate levels of certain transcripts in the distal axon, suggesting that the specific susceptibility of motoneurons to SMN deficiency is related to a specialized function in these cells. Although mouse models of SMA have been generated and are useful for in vivo and in vitro studies, the limited number of isolated MNs that could be obtained from them makes it difficult to perform biochemical, genetic and pharmacological approaches. We describe here an in vitro model of isolated embryonic mouse motoneurons in which the cellular levels of endogenous SMN are reduced. These cells show neurite degeneration and cell death after several days of SMN knockdown. We found that the over-expression of the anti-apoptotic protein Bcl-xL into motoneurons rescues these cells from the phenotypic changes observed. This result demonstrates that Bcl-xL signaling could be a possible pharmacological target of SMA therapeutics.
KW - Bcl-xL
KW - Motoneuron
KW - Neurotrophic factors
KW - Spinal Muscular Atrophy
KW - Survival Motor Neuron
UR - http://www.scopus.com/inward/record.url?scp=79954631444&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2011.02.003
DO - 10.1016/j.nbd.2011.02.003
M3 - Article
C2 - 21333739
AN - SCOPUS:79954631444
SN - 0969-9961
VL - 42
SP - 415
EP - 426
JO - Neurobiology of Disease
JF - Neurobiology of Disease
IS - 3
ER -